Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Chagas disease wikipedia , lookup
Leptospirosis wikipedia , lookup
Onchocerciasis wikipedia , lookup
Whooping cough wikipedia , lookup
Schistosomiasis wikipedia , lookup
Meningococcal disease wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Hospital-acquired infection wikipedia , lookup
Risk of invasive H. influenzae disease in patients with chronic renal failure: a call for vaccination? M. Ulanova, S. Gravelle, N. Hawdon, S. Malik, D. Vergidis, and W. McCready Lake Superior Secondary Immunodeficiency States The immune system’s ability to fight infections is compromised Result of severe chronic organ diseases, aging, or use of immunosuppressive therapies Examples: Chronic liver disease Chronic kidney disease Diabetes mellitus Leukemias Multiple myeloma Bone marrow transplantation Cytostatic drugs, corticosteroids, etc Chronic Kidney Disease (CKD) Among ≥65 yr old adults in USA, 20% have CKD ESRD: stage 5 CKD requiring renal replacement therapy Over 700,000 ESRD patients by 2015 (USA) In ESRD patients, 1-yr mortality: 20% 5-yr mortality: over 60% Increased prevalence of ESRD in Aboriginal people in Canada; mainly caused by diabetic nephropathy In Northwestern Ontario, 36.6% of ESRD patients undergoing dialysis: Aboriginal (2008) Impaired Host Immune Response in ESRD Patients • Decreased granulocyte and monocyte/macrophage phagocytic function • Defective antigen presentation by monocytes and macrophages • Reduced antibody production by B lymphocytes • Impaired T-cell mediated immunity Factors Causing Immune Dysfunction in ESRD Patients • The uremic state and its metabolic consequences - Accumulation of toxic waste products - Chronic malnutrition and anemia • Underlying diseases which led to renal failure • Immunosuppressive drugs used to treat and control underlying diseases • Dialysis procedure • Multiple blood transfusions Risk Factors of Infection in Kidney Disease Comorbid Conditions • Advanced Age • Diabetes Mellitus • Other Systemic Diseases Impaired Immune Response • T- and Blymphocytes • Neutrophils • Monocytes Decreased Vaccine Responsiveness Increased Exposure to Infectious Agents ACUTE INFECTION Immunosuppressive Therapy Disruption of Cutaneus Barriers Infections in ESRD Second major cause of death Most common: 1) urinary tract infections, 2) pneumonia, 3) sepsis Also cellulitis, peritonitis, endocarditis, meningitis Annual mortality rates in the dialysis population compared with the general population: - 10-fold higher for pneumonia - 100-fold higher for sepsis (Sarnak et al, Chest, 2001) (Sarnak et al, Kidney Int, 2000) Vaccinations recommended for adults with CKD and patients undergoing dialysis Pneumococcal 23-valent polysaccharide vaccine Influenza vaccine Hepatitis virus B vaccine Varicella vaccine According to The Canadian Immunization Guide (2006) Haemophilus influenzae • Gram-negative bacterium • The polysaccharide capsule protects bacteria from host defense • Six serotypes of encapsulated H. influenzae: a, b, c, d, e, f Most virulent: Hib • Non-encapsulated H. influenzae www.wadsworth.org/databank /images/haemophilus Haemophilus influenzae • Nasopharyngeal colonization in healthy individuals • Cause invasive diseases: meningitis, sepsis, and bacteremic pneumonia, mainly in children • Circulating IgG antibody: the major defense mechanism • Natural immunity develops with age • Young children: delay in immune responses • Pediatric vaccine against H. influenzae type b (Hib): dramatic decline in disease incidence • Adult vaccination is recommended for high-risk groups (e.g. asplenia) • In some Aboriginal populations: increased susceptibility to invasive H. influenzae disease Our recent findings: high incidence of invasive H. influenzae disease caused by non-type b strains in Northwestern Ontario Incidence Rate per 100, 000 3.5 3 2.5 2 Invasive H. influenzae disease: Northwestern Ontario 2002-2008 1.5 1 0.5 Invasive Hib disease: Ontario1989-2004* 0 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 Year *Public Health Agency of Canada Notifiable Diseases, 2006 Brown V, Madden S, Kelly L, Jamieson F, Tsang R, Ulanova M. Invasive Haemophilus influenzae disease caused by non-type b strains in Northwestern Ontario, Canada, 2002-2008. Clin Infect Dis 2009, 49:1240-1243. • 38 cases of invasive H. influenzae disease • High ncidence rate: H.2.98/100.000 influenzae in 2004, Northwestern Ontario 2006, and 2007 Hib Ontario • Increased prevalence of the disease among 1) First Nations children <5 yr 2) Adults with predisposing medical conditions Do patients with diabetic nephropathy and ESRD have an increased risk of invasive H. influenzae type b disease? Rationale: • Diabetic nephropathy: the most common cause of chronic renal failure • Both diabetes and ESRD cause immunosuppression • Hib continues circulating in Canada • Adults have not been immunized against Hib • Cases of peritonitis caused by Hib are described Methodology 28 ESRD patients with type 2 diabetes mellitus (DM) undergoing peritoneal or haemodialysis (50% First Nations, age 37-83) 15 patients with DM and normal kidney function (age 45-76) 38 healthy controls (42% First Nations, age 22-77) Analysis of serum IgG antibody levels against H. influenzae type b (Hib) capsular polysaccharide (ELISA) Antibody level ensuring long-term protection: 1 mg/ml Morbidity in ESRD Patients Type 2 Diabetes Mellitus 25/25 Cardiovascular Disease 18/25 COPD 7/25 Hypothyroidism Mental Illness Multiple Infectious Episodes 20/25 Pneumonia 9/25 Sepsis 6/25 Cellulitis/Infected Ulcers 5/25 Urinary Tract Infection 3/25 Septic Arthritis 1/25 Osteomyelitis 1/25 Peritonitis 1/25 Otitis media 1/25 3/25 3/25 Serum IgG antibody levels to H. influenzae type b Median 2.41 2.73 0.47 Range 0 - 8.1 0 - 13.5 0 - 22.0 P<0.05 Antibody against H. influenzae type b in patients with ESRD and diabetes mellitus Patient Group Controls Lack of protective Ab (1 mg/ml) 13% (5 out of 38 ) Diabetes Mellitus 33% (5 out of 15) ESRD + Diabetes 61% (17 out of 28) Over 60% of patients with ESRD lack protective anti-Hib antibodies Discussion With pediatric Hib vaccine widely used, circulation of Hib is decreasing Decreased natural exposure to Hib in nonvaccinated individuals Lack of natural boosting of anti-Hib immunity Discussion With pediatric Hib vaccine widely used, circulation of Hib is decreasing ESRD patients are immunocompromized (secondary immunodeficiency) Decreased natural exposure to Hib in nonvaccinated individuals Lack of natural boosting of anti-Hib immunity Increased risk of Hib invasive disease Conclusions • Pediatric Hib vaccine is safe and efficient in adults • It may be beneficial to immunize adult ESRD patients with the pediatric Hib vaccine to achieve protective antibody level • Next questions: Can vaccination provide long-lasting protection? What about other groups of ESRD patients? Acknowledgements Financial Support: Patients at TBRHSC Renal Services and Dr Malik’s Office Volunteers: healthy controls Donna Newhouse Personnel at TBRHSC and physicians’ offices Founding Dean Summer Medical Student Research Award to Sean Gravelle Dr McCready’s NOSM Internal Research Funding Dr Ulanova’s NOSM Internal Research Funding